Source: MarketScreener

Lee's Pharm: Lee's Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

( China Oncology Focus, a subsidiary of Lee's Pharm, has enrolled the first patient in the Socazolimab double-blinded Phase 3 study in combination with chemotherapy as a first-line treatment of extensive-stage small-cell lung cancer.Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by...

Read full article »
Est. Annual Revenue
Est. Employees
CEO Avatar


Update CEO

CEO Approval Rating

- -/100

Lee's Pharm is a Private company. Lee's Pharm generates $1M in revenue per employee Lee's Pharm has 2 followers on Owler.